Orexo has announced the U.S. Food and Drug Administration (FDA) has approved Edluar (formerly Sublinox) 5 mg and 10 mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
Meda, Orexo’s partner, acquired exclusive worldwide commercial licensing for Edluar in 2008 with expectations to launch the product in the U.S. market during the second half of 2009. Orexo will receive royalties based on Meda’s sales of Edluar.
Obstructive sleep apnea (OSA) affects up to 20 percent of men in western cultures, five percent of whom experience significant physical symptoms.
A study published in September 2006 issue of the Journal of Forensic Sciences finds that sex offenders who suffer from obstructive sleep apnea experience more harmful psychological symptoms than do sex offenders with normal sleep patterns.
This is a 2D-barcode containing the address of our mobile site.If your mobile has a barcode reader, simply snap this bar code with the camera and launch the site.
Many companies provide barcode readers that you can install on your mobile, and all of the following are compatible with this format:
As of May 2, 2009 at 9:47 p.m. (-0500) (ET), the U.S. population
was 306,340,710. Sleep researchers estimate approximately seven percent
of the population suffers from obstructive sleep apnea. Using that
estimate, there are potentially 21,443,850 apneics in the U.S.
~~ Apnea around the world ~~
As of May 2, 2009 at 9:47 p.m. (-0500) (ET), the world population
was 6,777,286,604. Sleep researchers estimate approximately seven percent
of the population suffers from obstructive sleep apnea. Using that
estimate, there are potentially 474,410,062 apneics in the world.
